Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival ("PFS") Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Hazard Ratios and Improvements in Median PFS are U

Celcuity Announces Clinically Meaningful Improvement

in Both Progression-Free Survival ("PFS") Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial

Hazard Ratios and Improvements in Median PFS

Unprecedented in HR+/HER2- Advanced Breast Cancer

MINNEAPOLIS, July 28, 2025 - Celcuity Inc. (Nasdaq: CELC),

a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced positive topline results

from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib plus fulvestrant with and without

palbociclib versus fulvestrant in adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative,

PIK3CA wild-type, locally advanced or metastatic breast cancer, following progression on, or after, treatment with a CDK4/6 inhibitor

and an aromatase inhibitor.

In the trial, the gedatolisib triplet demonstrated a statistically

significant and clinically meaningful improvement in PFS among patients, reducing the risk of disease progression or death by 76% compared

to fulvestrant (based on a hazard ratio [HR] of 0.24, 95% confidence interval [CI] 0.17-0.35; p<0.0001). The mPFS, as assessed by blinded

independent central review ("BICR"), was 9.3 months with the gedatolisib triplet versus 2.0 months with fulvestrant, an incremental

improvement of 7.3 months.

The gedatolisib doublet also demonstrated a statistically significant

and clinically meaningful improvement in PFS among patients, reducing the risk of disease progression or death by 67% compared to fulvestrant

(HR of 0.33, 95% CI 0.24-0.48; p<0.0001). The mPFS, as assessed by BICR, was 7.4 months with the gedatolisib doublet versus 2.0 months

with fulvestrant, an incremental improvement of 5.4 months.

The topline efficacy data from the VIKTORIA-1 PIK3CA wild-type

cohort established several new milestones in the history of drug development for HR+/HER2- advanced breast cancer:

Sara Hurvitz, MD, Senior Vice President, Clinical Research Division,

Fred Hutchinson Cancer Center, Professor and Head, Division of Hematology and Oncology, University of Washington, Department of Medicine

and co-principal investigator for the trial said: "Patients with HR-positive, HER2-negative, PIK3CA wild-type advanced breast

cancer whose disease has progressed while on, or after, treatment with a CDK4/6 inhibitor typically derive limited benefit from subsequent

endocrine-based therapy. The topline data for both gedatolisib regimens from VIKTORIA-1 are potentially practice-changing. To my knowledge,

we have not seen Phase 3 results in patients with HR-positive, HER2-negative advanced breast cancer before where there was a quadrupling

of the likelihood of survival without disease progression relative to the study control."

Treatment discontinuation due to a treatment-related adverse event

for the gedatolisib triplet and gedatolisib doublet was lower than was observed in Arm D of the Phase 1b trial in patients with ABC, and

lower than observed in any Phase 3 trials for currently approved drug combinations in HR+/HER2- ABC. Additionally, the gedatolisib triplet

and gedatolisib doublet were better tolerated than was observed in the Phase 1b trial in patients with ABC, including lower rates of hyperglycemia

Igor Gorbatchevsky, MD, Chief Medical Officer of Celcuity said: "The

topline data from VIKTORIA-1 demonstrate the potential for gedatolisib to become a transformative new medicine for the treatment of patients

with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer whose disease progressed on or after treatment with CDK4/6

inhibitors. The 7.3 and 5.4-months incremental improvement in median PFS relative to fulvestrant for the gedatolisib regimens are potentially

paradigm shifting results. We are also very excited that treatment with gedatolisib combined with fulvestrant with or without palbociclib

was well-tolerated by the VIKTORIA-1 patients and that only a few patients discontinued treatment due to an adverse event."

Brian Sullivan, Chairman, Chief Executive Officer and co-founder of

Celcuity said, "The efficacy improvement relative to the control that each of the gedatolisib regimens demonstrated was historic

for this patient population. We are excited about the potential opportunity to provide a breakthrough therapeutic option for patients

with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer."

Full data from the PIK3CA wild-type cohort of the VIKTORIA-1

clinical trial will be presented at an upcoming medical conference later this year. Celcuity expects to submit a New Drug Application

for gedatolisib to the U.S. Food and Drug Administration in the fourth quarter of 2025. Topline data for the VIKTORIA-1 PIK3CA

mutation cohort is expected by the end of 2025.

Webcast and Conference Call Information

The Celcuity management team will host a webcast/conference

call on Monday, July 28, 2025, at 8:00 a.m. ET to discuss the topline results from the Phase 3 VIKTORIA-1 trial. Those who would like

to participate may access the live webcast here, or register in advance for the teleconference here. A replay of the webcast

will be available on the Celcuity website following the live event.

HR+/HER2- Breast cancer

Breast cancer is the second most common cancer and one of the leading

causes of cancer-related deaths worldwide.1 More than two million breast cancer cases were diagnosed globally in 2022.1

While survival rates are high for those diagnosed with early breast cancer, only approximately 30% of patients who are diagnosed with

or who progress to metastatic disease are expected to live five years after their diagnosis.2 HR+/HER2- breast cancer is the

most common subtype of breast cancer, accounting for approximately 70% of all breast cancers.2

Three interconnected signaling pathways, estrogen, cyclin D1-CDK4/6,

and PI3K/AKT/mTOR (PAM), are primary oncogenic drivers of HR+, HER2- breast cancer.3 Therapies inhibiting these pathways are

approved and used in various combinations for advanced breast cancer. Currently approved inhibitors of the PAM pathway for breast cancer

target a single PAM pathway component, such as PI3K , AKT, or mTORC1.4,5,6,7 However, resistance to CDK4/6 inhibitors

and current endocrine therapies develops in many patients with advanced disease.8 Survival rates are low with 30% of patients

anticipated to live beyond five years after diagnosis.2 Optimizing the inhibition of the PAM pathway is an active area of focus

for breast cancer research.

VIKTORIA-1 is a Phase 3 open-label, randomized clinical trial to evaluate

the efficacy and safety of gedatolisib in combination with fulvestrant with or without palbociclib in adults with HR+/HER2- ABC whose

disease progressed on or after prior CDK4/6 therapy in combination with an aromatase inhibitor. The clinical trial is enrolling subjects

regardless of PIK3CA status while enabling separate evaluation of subjects according to their PIK3CA status. Subjects who

meet eligibility criteria and do not have confirmed PI3KCA mutations (WT) were randomly assigned (1:1:1) to receive a regimen of

either gedatolisib, palbociclib, and fulvestrant, gedatolisib and fulvestrant, or fulvestrant. Subjects who meet eligibility criteria

and have confirmed PI3KCA mutations (MT) are randomly assigned (3:3:1) to receive a regimen of either the gedatolisib triplet,

alpelisib and fulvestrant, or the gedatolisib doublet.

Gedatolisib is an investigational, multi-target PAM inhibitor that

potently targets all four class I PI3K isoforms, mTORC1, and mTORC2 to induce comprehensive blockade of the PAM pathway.9,10,11

As a multi-target PAM inhibitor, gedatolisib's mechanism of action is highly differentiated from currently approved single-target

inhibitors of the PAM pathway.11 Inhibition of only a single PAM component gives tumors an escape mechanism through cross-activation

of the uninhibited targets. Gedatolisib's comprehensive PAM pathway inhibition ensures full suppression of PAM activity by eliminating

adaptive resistance cross-activation that occurs with single-target inhibitors. Unlike single-target inhibitors of the PAM pathway, gedatolisib

has demonstrated equal potency and comparable cytotoxicity in PIK3CA-mutant and -wild-type breast tumor cells in nonclinical studies

and early clinical data.11,12

is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications.

The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the

PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational

therapies that target PI3K , AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in

combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration

resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant

as first-line treatment for patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information

about Celcuity's active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further

Forward-Looking Statements

This press release contains statements that constitute "forward-looking

statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements relating to the potential

therapeutic benefits of gedatolisib; the size, design and timing of our clinical trials; our interpretation of topline clinical trial

data; the ability of our data to support the filing of an NDA with the FDA; our expectations regarding the timing of and our ability to

obtain FDA approval to commercialize gedatolisib; and other expectations with respect to gedatolisib. Words such as, but not limited to,

"look forward to," "believe," "expect," "anticipate," "estimate," "intend,"

"confidence," "encouraged," "potential," "plan," "targets," "likely,"

"may," "will," "would," "should" and "could," and similar expressions or words

identify forward-looking statements. The forward-looking statements included in this press release are based on management's current expectations

and beliefs which are subject to a number of risks, uncertainties and factors, including that our topline results are based on a preliminary